LMAT LEMAITRE VASCULAR INC

Nasdaq lemaitre.com


$ 87.24 $ -0.12 (-0.14 %)    

Wednesday, 15-Oct-2025 15:59:54 EDT
QQQ $ 605.00 $ 0.00 (0 %)
DIA $ 464.36 $ 0.00 (0 %)
SPY $ 667.26 $ 0.00 (0 %)
TLT $ 90.91 $ 0.00 (0 %)
GLD $ 389.21 $ 0.00 (0 %)
$ 87.26
$ 87.12
$ 85.10 x 4
$ 90.15 x 6
-- - --
$ 71.10 - $ 108.82
98,959
na
1.98B
$ 0.67
$ 41.93
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-06-2019 03-31-2019 10-Q
27 03-11-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-06-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 03-09-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barrington-research-maintains-outperform-on-lemaitre-vascular-maintains-95-price-target

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and maintains $95 pr...

 barrington-research-maintains-outperform-on-lemaitre-vascular-maintains-95-price-target

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and maintains $95 pr...

 cantor-fitzgerald-maintains-neutral-on-lemaitre-vascular-raises-price-target-to-95

Cantor Fitzgerald analyst Ross Osborn maintains LeMaitre Vascular (NASDAQ:LMAT) with a Neutral and raises the price target f...

 barrington-research-upgrades-lemaitre-vascular-to-outperform-announces-95-price-target

Barrington Research analyst Michael Petusky upgrades LeMaitre Vascular (NASDAQ:LMAT) from Market Perform to Outperform and a...

 lemaitre-vascular-sees-q3-gaap-eps-054-059-vs-054-est-sees-sales-61200m-63200m-vs-60923m-est

LeMaitre Vascular (NASDAQ:LMAT) is looking for Q3 GAAP EPS of $0.54-$0.59 vs $0.54 analyst estimate. sees sales of $61.200 mill...

 lemaitre-vascular-raises-fy2025-gaap-eps-guidance-from-207-224-to-223-237-vs-215-est-raises-fy2025-sales-guidance-from-242000m-249000m-to-248000m-254000m-vs-245469m-est

LeMaitre Vascular (NASDAQ:LMAT) raises FY2025 GAAP EPS guidance from $2.07-$2.24 to $2.23-$2.37 vs $2.15 analyst estimate. Rais...

 lemaitre-vascular-q2-eps-060-beats-057-estimate-sales-64232m-beat-62480m-estimate

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0....

 barrington-research-reiterates-market-perform-on-lemaitre-vascularto-market-perform

Barrington Research analyst Michael Petusky reiterates LeMaitre Vascular (NASDAQ:LMAT) from Market Perform to Market Perform.

 lemaitre-vascular-lowers-fy2025-gaap-eps-guidance-from-215-232-to-207-224-vs-224-est-raises-fy2025-sales-guidance-from-23540m-24280m-to-24200m-24900m-vs-23926m-est

LeMaitre Vascular (NASDAQ:LMAT) lowers FY2025 GAAP EPS guidance from $2.15-$2.32 to $2.07-$2.24 vs $2.24 analyst estimate. Rais...

 lemaitre-vascular-sees-q2-gaap-eps-055-059-vs-058-est-sees-sales-61500m-63500m-vs-6087m-est

LeMaitre Vascular (NASDAQ:LMAT) is looking for Q2 GAAP EPS of $0.55-$0.59 vs $0.58 analyst estimate. sees sales of $61.500 mill...

 lemaitre-vascular-q1-eps-048-misses-050-estimate-sales-5987m-beat-5764m-estimate

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.48 per share which missed the analyst consensus estimate of $...

 lake-street-maintains-buy-on-lemaitre-vascular-raises-price-target-to-110

Lake Street analyst Brooks O'Neil maintains LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises the price target from ...

 citizens-capital-markets-maintains-buy-on-lemaitre-vascular-raises-price-target-to-110

Citizens Capital Markets analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises the price ta...

 barrington-research-downgrades-lemaitre-vascular-to-market-perform

Barrington Research analyst Michael Petusky downgrades LeMaitre Vascular (NASDAQ:LMAT) from Outperform to Market Perform.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION